Analysts' ratings for Harmony Biosciences (NASDAQ:HRMY) over the last quarter vary from bullish to bearish, as provided by 7 analysts.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have set 12-month price targets for Harmony Biosciences, revealing an average target of $60.43, a high estimate of $75.00, and a low estimate of $52.00. This current average reflects an increase of 7.28% from the previous average price target of $56.33.

Diving into Analyst Ratings: An In-Depth Exploration

An in-depth analysis of recent analyst actions unveils how financial experts perceive Harmony Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Harmony Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Harmony Biosciences analyst ratings.

Discovering Harmony Biosciences: A Closer Look

A Deep Dive into Harmony Biosciences's Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Harmony Biosciences's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 16.08%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Harmony Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.78% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Harmony Biosciences's ROE excels beyond industry benchmarks, reaching 8.12%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Harmony Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.16% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Harmony Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.